Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

NCT06372626 is registered in ClinicalTrials.gov with Suzhou Zelgen Biopharmaceuticals Co.,Ltd as lead sponsor.

NCT NCT06372626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06372626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
Lead sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 30, 2024
Completion date
August 31, 2026
Enrollment
93 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinoma